Granules India posts Q4 FY25 PAT at Rs. 152 Cr

The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility

Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr

The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations

Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr

Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24

Granules India launches 'Breast Health Express' mobile unit

The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need

Budget 2024-25: Industry expects push for reforms, R&D and fiscal incentives

Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23

Briefs: Aurobindo Pharma and Granules Pharmaceuticals

Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection

Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr

Sales in the US region grew well, partially offset by the decline in the LATAM and European regions

Advent International announces the completion of the acquision of Suven Pharma

New Board of Directors and management team at Suven Pharma also appointed

Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr

API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24

Granules India received USFDA approval for the ANDA filed for metoprolol succinate ER tablets